Neos Therapeutics Company Profile (NASDAQ:NEOS)

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEOS
  • CUSIP: N/A
  • Web: www.neostx.com
Capitalization:
  • Market Cap: $184.99 million
  • Outstanding Shares: 22,560,000
Average Prices:
  • 50 Day Moving Avg: $7.33
  • 200 Day Moving Avg: $6.76
  • 52 Week Range: $4.85 - $11.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.43
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $12.2 million
  • Price / Sales: 15.16
  • Book Value: $0.56 per share
  • Price / Book: 14.64
Profitability:
  • EBIDTA: ($77,120,000.00)
  • Net Margins: -1,013.17%
  • Return on Equity: -144.74%
  • Return on Assets: -64.00%
Debt:
  • Debt-to-Equity Ratio: 3.68%
  • Current Ratio: 3.36%
  • Quick Ratio: 3.10%
Misc:
  • Average Volume: 293,717 shs.
  • Beta: -0.92
  • Short Ratio: 7.17
 

Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics Inc (NASDAQ:NEOS) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.07. The business had revenue of $5.63 million for the quarter. Neos Therapeutics had a negative return on equity of 144.74% and a negative net margin of 1,013.17%. View Neos Therapeutics' Earnings History.

Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?

3 analysts have issued 12 month price targets for Neos Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they expect Neos Therapeutics' stock price to reach $17.50 in the next twelve months. View Analyst Ratings for Neos Therapeutics.

Who are some of Neos Therapeutics' key competitors?

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Who owns Neos Therapeutics stock?

Neos Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include DAMMEYER RODNEY F (6.20%), Vanguard Group Inc. (2.61%), UBS Group AG (0.48%), Columbus Circle Investors (0.47%), Russell Investments Group Ltd. (0.45%) and Geode Capital Management LLC (0.41%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell. View Institutional Ownership Trends for Neos Therapeutics.

Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?

Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Neos Therapeutics.

Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?

Neos Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Columbus Circle Investors, Hunter Associates Investment Management LLC, Sheaff Brock Investment Advisors LLC, Wells Fargo & Company MN, Mission Wealth Management LLC, Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell. View Insider Buying and Selling for Neos Therapeutics.

How do I buy Neos Therapeutics stock?

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Neos Therapeutics stock cost?

One share of Neos Therapeutics stock can currently be purchased for approximately $8.20.

Analyst Ratings

Consensus Ratings for Neos Therapeutics (NASDAQ:NEOS) (?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $17.50 (113.41% upside)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017ValuEngineUpgradeStrong Sell -> SellLowView Rating Details
4/5/2017Cowen and CompanyInitiated CoverageOutperform$20.00HighView Rating Details
3/11/2017BMO Capital MarketsReiterated RatingOutperform$15.00N/AView Rating Details
5/18/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
5/17/2016Royal Bank of CanadaLower Price TargetOutperform$33.00 -> $29.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Neos Therapeutics (NASDAQ:NEOS)
Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Earnings History by Quarter for Neos Therapeutics (NASDAQ:NEOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.94)($0.87)$5.63 millionViewListenView Earnings Details
3/14/2017Q4 2016($1.36)($1.14)$3.50 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.64)($1.61)$1.58 millionViewN/AView Earnings Details
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)$1.50 million$2.58 millionViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-3.23 EPS
Next Year EPS Consensus Estimate: $-1.51 EPS

Dividends

Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ:NEOS)
Insider Ownership Percentage: 4.85%
Institutional Ownership Percentage: 34.32%
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.00View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.20View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neos Therapeutics (NASDAQ:NEOS)
Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
Source:
DateHeadline
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 11:34 PM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 18 at 3:28 PM
finance.yahoo.com logoNeos Therapeutics to Present at 2017 UBS Global Healthcare Conference
finance.yahoo.com - May 16 at 10:15 AM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 14 at 9:12 AM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 10 at 4:56 PM
globenewswire.com logoNeos Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 11:34 AM
marketbeat.com logoNeos Therapeutics reports 1Q loss
marketbeat.com - May 9 at 9:41 AM
americanbankingnews.com logoZacks: Analysts Expect Neos Therapeutics Inc (NEOS) Will Post Earnings of -$0.89 Per Share
www.americanbankingnews.com - May 4 at 10:50 PM
americanbankingnews.com logoNeos Therapeutics (NEOS) Earns Daily Coverage Optimism Rating of 0.24
www.americanbankingnews.com - May 3 at 11:18 PM
finance.yahoo.com logoNeos Therapeutics to Host First Quarter 2017 Financial Results Conference Call on May 9, 2017
finance.yahoo.com - May 2 at 2:37 PM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 9:32 AM
americanbankingnews.com logoNeos Therapeutics (NEOS) Earns Daily Media Impact Score of -0.04
www.americanbankingnews.com - April 27 at 6:24 PM
americanbankingnews.com logoNeos Therapeutics (NEOS) Receives Daily Media Sentiment Score of 0.17
www.americanbankingnews.com - April 24 at 8:48 PM
americanbankingnews.com logoNeos Therapeutics (NEOS) Receives News Sentiment Score of 0.28
www.americanbankingnews.com - April 22 at 12:17 AM
americanbankingnews.com logoShort Interest in Neos Therapeutics Inc (NEOS) Rises By 7.5%
www.americanbankingnews.com - April 20 at 5:56 PM
americanbankingnews.com logoNeos Therapeutics (NEOS) Receives Media Impact Score of -0.12
www.americanbankingnews.com - April 17 at 3:58 PM
americanbankingnews.com logoNeos Therapeutics (NEOS) Given Daily Media Sentiment Rating of 0.03
www.americanbankingnews.com - April 14 at 2:52 PM
americanbankingnews.com logoZacks: Brokerages Expect Neos Therapeutics Inc (NEOS) Will Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - April 13 at 8:30 PM
bloomberg.com logoBloomberg Markets: Dave Wilson’s Stock of the Day for April 5
www.bloomberg.com - April 7 at 11:26 AM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Receives New Coverage from Analysts at Cowen and Company
www.americanbankingnews.com - April 6 at 12:25 AM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 2:39 PM
finance.yahoo.com logoNeos Therapeutics downgraded by UBS
finance.yahoo.com - March 20 at 4:55 PM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Lowered to “Hold” at Zacks Investment Research
www.americanbankingnews.com - March 18 at 8:46 AM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 6:58 PM
americanbankingnews.com logoNeos Therapeutics Inc (NEOS) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 15 at 10:10 AM
us.rd.yahoo.com logoNeos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 14 at 10:52 AM
biz.yahoo.com logoQ4 2016 Neos Therapeutics Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 14 at 10:52 AM
finance.yahoo.com logo7:09 am Neos Therapeutics reports Q4 results & provides a pipeline update
finance.yahoo.com - March 14 at 10:52 AM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - March 14 at 10:52 AM
streetinsider.com logoForm 8-K Neos Therapeutics, Inc. For: Mar 06 - StreetInsider.com
www.streetinsider.com - March 12 at 9:24 AM
americanbankingnews.com logoNeos Therapeutics’ (NEOS) “Outperform” Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - March 11 at 8:52 PM
finance.yahoo.com logoCan The Uptrend Continue for Neos Therapeutics (NEOS)?
finance.yahoo.com - March 10 at 8:06 PM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 10 at 8:06 PM
globenewswire.com logoNeos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017 - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:30 AM
zacks.com logoWhy Endo International (ENDP) Could Be Positioned for a Slump
www.zacks.com - March 8 at 9:40 AM
finance.yahoo.com logoNeos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017
finance.yahoo.com - March 8 at 9:40 AM
finance.yahoo.com logoGenocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher
finance.yahoo.com - March 8 at 9:40 AM
zacks.com logoShould You Get Rid of Valeant Pharmaceuticals International (VRX) Now?
www.zacks.com - March 6 at 8:12 AM
zacks.com logoNew Strong Buy Stocks for March 2nd
www.zacks.com - March 3 at 12:01 AM
finance.yahoo.com logo5 Stocks with Rising P/E to Enjoy Stellar Gains
finance.yahoo.com - March 2 at 9:15 AM
finance.yahoo.com logoNeos Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 10:23 AM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State
biz.yahoo.com - February 8 at 7:41 PM
rttnews.com logoNeos Therapeutics Prices Public Offering At $5/Shr
www.rttnews.com - February 6 at 6:51 PM
streetinsider.com logoPre-Open Movers 02/03: (PXLW) (DATA) (PTN) Higher; (DECK) (IDXG) (FEYE) (GPRO) (AMZN) Lower (more...)
www.streetinsider.com - February 3 at 7:33 PM
reuters.com logoBRIEF-Neos Therapeutics estimates that, for three months ended Dec. 31 total net product revenues were between $3.3 mln-$3.6 mln
www.reuters.com - February 3 at 7:33 PM
nasdaq.com logoNeos Therapeutics Announces Pricing of Underwritten Public Offering of $25.0 Million of Common Stock
www.nasdaq.com - February 3 at 7:33 PM
finance.yahoo.com logoWhy Neos Therapeutics Shares Are Hitting a New Low
finance.yahoo.com - February 3 at 7:33 PM
finance.yahoo.com logoNeos Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - February 2 at 7:41 PM
streetinsider.com logoNeos Therapeutics (NEOS) Completes XR-ODT NDA Resubmission
www.streetinsider.com - December 20 at 12:44 PM
us.rd.yahoo.com logo7:32 am Neos Therapeutics completes resubmission of a NDA to the FDA for Cotempla XR-ODT
us.rd.yahoo.com - December 20 at 12:44 PM

Social

Chart

Neos Therapeutics (NEOS) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff